Literature DB >> 15031666

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis.

Hyo Won Jung1, Seung Won Choi, Jung I L Choi, Byoung Se Kwon.   

Abstract

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease whose etiopathogenesis is not well understood. Although soluble (s) forms of 4-1BB (s4-1BB) and 4-1BB legand (s4-1BBL) have been detected in the sera of RA patients, their significance is not known. We compared the serum levels of s4-1BB and s4-1BBL in RA patients with those in systemic lupus erythematosus (SLE) and Behcet's disease (BD) patients. Serum levels of s4-1BB and s4-1BBL were significantly higher in RA patients compared with healthy controls, SLE or BD patients, and the abundance was correlated with disease severity in patients with RA. The serum levels of s4-1BB in RA patients were inversely corroborated with 4-1BB expression levels on activated T lymphocytes. In addition, there was a correlation between serum levels of s4-1BB and s4-1BBL. The augmented secretion of s4-1BB and s4-1BBL levels into the serum may reflect the clinical symptoms of RA and levels of s4-1BB and s4-1BBL in sera at the time of diagnosis may be indicative of the severity and outcome of RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031666     DOI: 10.1038/emm.2004.2

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  25 in total

Review 1.  Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.

Authors:  Alison M Gizinski; David A Fox; Sujata Sarkar
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

2.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

Review 3.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

Review 4.  Dual immunoregulatory pathways of 4-1BB signaling.

Authors:  Dass S Vinay; Kiweon Cha; Byoung S Kwon
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

5.  Levels of 4-1BB transcripts and soluble 4-1BB protein are elevated in the adipose tissue of human obese subjects and are associated with inflammatory and metabolic parameters.

Authors:  T H Tu; C-S Kim; J-H Kang; I S Nam-Goong; C W Nam; E S Kim; Y I Kim; J I Choi; T Kawada; T Goto; T Park; J H Yoon Park; M-S Choi; R Yu
Journal:  Int J Obes (Lond)       Date:  2013-11-27       Impact factor: 5.095

Review 6.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

Review 7.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

8.  The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Authors:  Kritika Kachapati; David E Adams; Yuehong Wu; Charles A Steward; Daniel B Rainbow; Linda S Wicker; Robert S Mittler; William M Ridgway
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

9.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

Review 10.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.